{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+mg&page=4",
    "query": {
      "intervention": "Rivaroxaban 2.5 mg",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 127,
    "total_pages": 13,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+mg&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+2.5+mg&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T09:08:40.233Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04878497",
      "title": "Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation",
        "Frailty",
        "Anticoagulant-induced Bleeding",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1000000,
      "start_date": "2021-03-30",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-05-07",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04878497"
    },
    {
      "nct_id": "NCT06831474",
      "title": "Excretion of Rivaroxaban in Human Breast Milk",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postpartum",
        "VTE Prophylaxis",
        "VTE (Venous Thromboembolism)",
        "Rivaroxaban",
        "Breastfeeding",
        "Breast Milk Collection"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 10 MG Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban 20 MG Oral Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2025-07",
      "completion_date": "2026-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06831474"
    },
    {
      "nct_id": "NCT04509193",
      "title": "A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116049,
      "start_date": "2020-08-21",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-15",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Whippany, New Jersey",
      "locations": [
        {
          "city": "Whippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04509193"
    },
    {
      "nct_id": "NCT02900170",
      "title": "Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Albert Einstein Healthcare Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2016-07",
      "completion_date": "2018-06-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900170"
    },
    {
      "nct_id": "NCT01578044",
      "title": "Dabigatran Adherence Pilot Intervention for Patients With Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01578044"
    },
    {
      "nct_id": "NCT04394234",
      "title": "A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Uterine Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Direct oral anticoagulant (DOACs)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 961985,
      "start_date": "2020-05-15",
      "completion_date": "2020-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Titusville, New Jersey",
      "locations": [
        {
          "city": "Titusville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04394234"
    },
    {
      "nct_id": "NCT03271450",
      "title": "The DARE Warfarin CER Study",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Deep Venous Thrombosis",
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "Dabigatran: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Apixaban: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Apixaban: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Apixaban: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Edoxaban: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin: extended treatment (e.g at least 90 days)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin: extended treatment (e.g at least 180 days)",
          "type": "DRUG"
        },
        {
          "name": "Warfarin: extended treatment (e.g at least 270 days)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 416000,
      "start_date": "2017-07-01",
      "completion_date": "2021-10-30",
      "has_results": false,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03271450"
    },
    {
      "nct_id": "NCT05009862",
      "title": "The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Peripheral Arterial Disease"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 2.5 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aspirin 81Mg Ec Tab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-04-19",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05009862"
    },
    {
      "nct_id": "NCT00395772",
      "title": "Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Xarelto (Rivaroxaban, BAY59-7939)",
          "type": "DRUG"
        },
        {
          "name": "(LMW) Heparin + Vitamin K Antagonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 543,
      "start_date": "2004-12",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2014-10-28",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 5,
      "location_summary": "Albuquerque, New Mexico • Chapel Hill, North Carolina • Fredericksburg, Virginia + 1 more",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Fredericksburg",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00395772"
    },
    {
      "nct_id": "NCT07613840",
      "title": "Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Arterial Disease (PAD)",
        "Amputation",
        "Thrombosis",
        "Thrombosis (Stent Thrombosis)",
        "Platelet Aggregation Inhibitors",
        "Thromboelastography (TEG)",
        "PRU(Platelet Reactivity Unit)"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Ticagrelor",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Thromboelastography with Platelet Mapping",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 484,
      "start_date": "2025-04-29",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-09T09:08:40.233Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Salem, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Salem",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07613840"
    }
  ]
}